The Remicade Drug Market is expected to register a CAGR of 9.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Remicade Drug Market report covers analysis by Product Type (Branded Drugs, Generic Drugs); Application (Crohn's Disease, Pediatric Crohn's Disease, Ulcerative Colitis, Pediatric Ulcerative Colitis, Other), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Remicade Drug Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Remicade Drug Market Segmentation
Product Type- Branded Drugs
- Generic Drugs
- Crohn's Disease
- Pediatric Crohn's Disease
- Ulcerative Colitis
- Pediatric Ulcerative Colitis
Strategic Insights
Remicade Drug Market Growth Drivers- Rising Prevalence of Autoimmune Diseases: An important factor driving the Remicade market is the rising prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. These diseases are more frequently diagnosed across the world, and therefore, the demand for effective biological treatments such as Remicade is also on the rise. The drug's ability to target specific inflammatory pathways makes it the first choice in the management of these chronic diseases.
- Increasing Acceptance of Biologic Therapies: Biologic drugs, such as Remicade, are widely used in medicine nowadays because they show high efficiency and targeted activity. Unlike most conventional oral drugs, Remicade exerts its effects by suppressing tumor necrosis factor (TNF), one of the leading causes of inflammation. This focused therapy is so efficient in dealing with autoimmune disorders, which accounts for its rapid acceptance in the field of clinical practice.
- Rise in Accessibility of Health Services: Access to healthcare in many developing regions is improving, and advanced biologic treatments will be received by more patients. An increased chance for Remicade to reach a large number of additional patients comes with the expansion of healthcare systems in emerging markets. The availability of drugs is better; thus, penetration of the drug in the market is improving.
- Trending Toward Biosimilars: Another significant trend in the market is the emergence of biosimilars following the patent expiration of Remicade in many markets. Biosimilars are essentially identical versions of the original biological drug. With their relatively lower cost as compared to branded Remicade, biosimilars are increasingly being prescribed. This has increased access to treatment but is also creating price competition in the market.
- Personalized Treatment Approaches: As personalized medicine gains momentum, treatment regimens that include drugs such as Remicade are becoming more customized to the individual needs of the patient. Genetic profiling and precision medicine are being used in the treatment of autoimmune diseases, thereby ensuring that the use of Remicade is targeted and improving the overall outcomes of patients. This trend is likely to make Remicade more effective and have a long-term market life.
- Combination Therapy in Disease Management: Combination therapies with Remicade are now becoming a standard. For the most part, Remicade is prescribed along with other immunosuppressants or corticosteroids to ensure the best treatment results for complicated autoimmune diseases. The trend towards multi-drug therapy is extending the range of applications of Remicade and providing further rationale for its maintenance in the therapeutic armamentarium.
- Development of New Indications: The existing approval of Remicade for several autoimmune diseases opens the scope for its application in more conditions. Studies may be conducted on the efficacy of the drug for other inflammatory conditions, including psoriasis, ankylosing spondylitis, and many other rare autoimmune diseases, thus expanding the drug's therapeutic profile and creating additional revenue streams.
- Focus on Aging Populations: Growing Ageing Population across the World: Now, a high percentage of this population is confronted with autoimmune diseases such as rheumatoid arthritis, so growing demand from the elderly population for effective treatment like Remicade can be considered an opportunity. The quality of life in older patients can be improved by the drug thus providing a new market opportunity, especially with the fast-rise number of elderly populations around the world.
- Strategic Collaborations and Licensing Deals: The partnerships between pharmaceutical companies and healthcare organizations can be an opportunity to increase the reach of Remicade. Strategic collaborations, including licensing agreements and distribution partnerships, can help enhance the availability of Remicade in under-served markets, further solidifying its position as a leading biologic therapy.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Remicade Drug Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Remicade Drug Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Remicade Drug Market are Rising Prevalence of Autoimmune Diseases, Increasing Acceptance of Biologic Therapies, and Rise in Accessibility of Health Services
The key future trends of the market are Trending Toward Biosimilars, Personalized Treatment Approaches, and Combination Therapy in Disease Management
The leading players operating in the Remicade Drug Market include Merck And Co, Celltrion Inc., NAPP Pharmaceuticals, Janssen Biotech Inc, PFIZER Inc, Alvogen, Nippon Kayaku, Amgen Inc., Ranbaxy Laboratories.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Remicade Drug Market - By Product Type
1.3.2 Remicade Drug Market - By Application
1.3.3 Remicade Drug Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. REMICADE DRUG MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. REMICADE DRUG MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. REMICADE DRUG MARKET - GLOBAL MARKET ANALYSIS
6.1. REMICADE DRUG - GLOBAL MARKET OVERVIEW
6.2. REMICADE DRUG - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. REMICADE DRUG MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. BRANDED DRUGS
7.3.1. Overview
7.3.2. Branded Drugs Market Forecast and Analysis
7.4. GENERIC DRUGS
7.4.1. Overview
7.4.2. Generic Drugs Market Forecast and Analysis
8. REMICADE DRUG MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. CROHN'S DISEASE
8.3.1. Overview
8.3.2. Crohn's Disease Market Forecast and Analysis
8.4. PEDIATRIC CROHN'S DISEASE
8.4.1. Overview
8.4.2. Pediatric Crohn's Disease Market Forecast and Analysis
8.5. ULCERATIVE COLITIS
8.5.1. Overview
8.5.2. Ulcerative Colitis Market Forecast and Analysis
8.6. PEDIATRIC ULCERATIVE COLITIS
8.6.1. Overview
8.6.2. Pediatric Ulcerative Colitis Market Forecast and Analysis
8.7. OTHER
8.7.1. Overview
8.7.2. Other Market Forecast and Analysis
9. REMICADE DRUG MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Remicade Drug Market Overview
9.1.2 North America Remicade Drug Market Forecasts and Analysis
9.1.3 North America Remicade Drug Market Forecasts and Analysis - By Product Type
9.1.4 North America Remicade Drug Market Forecasts and Analysis - By Application
9.1.5 North America Remicade Drug Market Forecasts and Analysis - By Countries
9.1.5.1 United States Remicade Drug Market
9.1.5.1.1 United States Remicade Drug Market by Product Type
9.1.5.1.2 United States Remicade Drug Market by Application
9.1.5.2 Canada Remicade Drug Market
9.1.5.2.1 Canada Remicade Drug Market by Product Type
9.1.5.2.2 Canada Remicade Drug Market by Application
9.1.5.3 Mexico Remicade Drug Market
9.1.5.3.1 Mexico Remicade Drug Market by Product Type
9.1.5.3.2 Mexico Remicade Drug Market by Application
9.2. EUROPE
9.2.1 Europe Remicade Drug Market Overview
9.2.2 Europe Remicade Drug Market Forecasts and Analysis
9.2.3 Europe Remicade Drug Market Forecasts and Analysis - By Product Type
9.2.4 Europe Remicade Drug Market Forecasts and Analysis - By Application
9.2.5 Europe Remicade Drug Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Remicade Drug Market
9.2.5.1.1 Germany Remicade Drug Market by Product Type
9.2.5.1.2 Germany Remicade Drug Market by Application
9.2.5.2 France Remicade Drug Market
9.2.5.2.1 France Remicade Drug Market by Product Type
9.2.5.2.2 France Remicade Drug Market by Application
9.2.5.3 Italy Remicade Drug Market
9.2.5.3.1 Italy Remicade Drug Market by Product Type
9.2.5.3.2 Italy Remicade Drug Market by Application
9.2.5.4 Spain Remicade Drug Market
9.2.5.4.1 Spain Remicade Drug Market by Product Type
9.2.5.4.2 Spain Remicade Drug Market by Application
9.2.5.5 United Kingdom Remicade Drug Market
9.2.5.5.1 United Kingdom Remicade Drug Market by Product Type
9.2.5.5.2 United Kingdom Remicade Drug Market by Application
9.2.5.6 Rest of Europe Remicade Drug Market
9.2.5.6.1 Rest of Europe Remicade Drug Market by Product Type
9.2.5.6.2 Rest of Europe Remicade Drug Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Remicade Drug Market Overview
9.3.2 Asia-Pacific Remicade Drug Market Forecasts and Analysis
9.3.3 Asia-Pacific Remicade Drug Market Forecasts and Analysis - By Product Type
9.3.4 Asia-Pacific Remicade Drug Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Remicade Drug Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Remicade Drug Market
9.3.5.1.1 Australia Remicade Drug Market by Product Type
9.3.5.1.2 Australia Remicade Drug Market by Application
9.3.5.2 China Remicade Drug Market
9.3.5.2.1 China Remicade Drug Market by Product Type
9.3.5.2.2 China Remicade Drug Market by Application
9.3.5.3 India Remicade Drug Market
9.3.5.3.1 India Remicade Drug Market by Product Type
9.3.5.3.2 India Remicade Drug Market by Application
9.3.5.4 Japan Remicade Drug Market
9.3.5.4.1 Japan Remicade Drug Market by Product Type
9.3.5.4.2 Japan Remicade Drug Market by Application
9.3.5.5 South Korea Remicade Drug Market
9.3.5.5.1 South Korea Remicade Drug Market by Product Type
9.3.5.5.2 South Korea Remicade Drug Market by Application
9.3.5.6 Rest of Asia-Pacific Remicade Drug Market
9.3.5.6.1 Rest of Asia-Pacific Remicade Drug Market by Product Type
9.3.5.6.2 Rest of Asia-Pacific Remicade Drug Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Remicade Drug Market Overview
9.4.2 Middle East and Africa Remicade Drug Market Forecasts and Analysis
9.4.3 Middle East and Africa Remicade Drug Market Forecasts and Analysis - By Product Type
9.4.4 Middle East and Africa Remicade Drug Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Remicade Drug Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Remicade Drug Market
9.4.5.1.1 South Africa Remicade Drug Market by Product Type
9.4.5.1.2 South Africa Remicade Drug Market by Application
9.4.5.2 Saudi Arabia Remicade Drug Market
9.4.5.2.1 Saudi Arabia Remicade Drug Market by Product Type
9.4.5.2.2 Saudi Arabia Remicade Drug Market by Application
9.4.5.3 U.A.E Remicade Drug Market
9.4.5.3.1 U.A.E Remicade Drug Market by Product Type
9.4.5.3.2 U.A.E Remicade Drug Market by Application
9.4.5.4 Rest of Middle East and Africa Remicade Drug Market
9.4.5.4.1 Rest of Middle East and Africa Remicade Drug Market by Product Type
9.4.5.4.2 Rest of Middle East and Africa Remicade Drug Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Remicade Drug Market Overview
9.5.2 South and Central America Remicade Drug Market Forecasts and Analysis
9.5.3 South and Central America Remicade Drug Market Forecasts and Analysis - By Product Type
9.5.4 South and Central America Remicade Drug Market Forecasts and Analysis - By Application
9.5.5 South and Central America Remicade Drug Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Remicade Drug Market
9.5.5.1.1 Brazil Remicade Drug Market by Product Type
9.5.5.1.2 Brazil Remicade Drug Market by Application
9.5.5.2 Argentina Remicade Drug Market
9.5.5.2.1 Argentina Remicade Drug Market by Product Type
9.5.5.2.2 Argentina Remicade Drug Market by Application
9.5.5.3 Rest of South and Central America Remicade Drug Market
9.5.5.3.1 Rest of South and Central America Remicade Drug Market by Product Type
9.5.5.3.2 Rest of South and Central America Remicade Drug Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL REMICADE DRUG MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. REMICADE DRUG MARKET, KEY COMPANY PROFILES
12.1. MERCK AND CO
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CELLTRION INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. NAPP PHARMACEUTICALS
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. JANSSEN BIOTECH INC.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ALVOGEN
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. NIPPON KAYAKU
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. AMGEN INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. RANBAXY LABORATORIES
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SAMSUNG BIOEPIS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Merck And Co
2. Celltrion Inc.
3. NAPP Pharmaceuticals
4. Janssen Biotech Inc
5. PFIZER Inc
6. Alvogen
7. Nippon Kayaku
8. Amgen Inc.
9. Ranbaxy Laboratories
10. Samsung Bioepis
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For